Although diabetes or prediabetes risk persists during ART, our observation that it is only apparent by HbA1c suggests that during ART, hepatic insulin resistance may be a driver of hyperglycemia, possibly due to liver fat accumulation or other adverse effects of ART drugs [38, 39]. This evidence concerns the gene INS and Hyperglycemia.